Considering the overall response of NHL patients to venetoclax monotherapy [22], these data collectively indicate that combination with CDK9 inhibitors may overcome mechanism of clinically relevant resistance to venetoclax monotherapy. This evidence concerns the gene CDK9 and non-Hodgkin lymphoma.